Coagulation Markers Market Report 2025

This Coagulation Markers market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The coagulation markers market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular diseases, an aging population, increasing surgical procedures, awareness and early diagnosis, government initiatives and funding, and expanding healthcare infrastructure.

The coagulation markers market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to a growing incidence of chronic diseases, rising adoption of personalized medicine, a growing global population, rising healthcare expenditures, and expansion in emerging markets. Major trends in the forecast period include the integration of AI and machine learning, the development of novel biomarkers, enhanced point-of-care technologies, automation in laboratories, wearable health technologies, telehealth and remote monitoring, and sustainable diagnostic practices.

The coagulation markers market is expected to grow significantly due to the increasing prevalence of blood disorders. These disorders encompass various conditions that impact the blood's ability to function properly, and their prevalence is rising due to factors such as aging populations, improved awareness, and enhanced diagnostic capabilities. Coagulation markers play a crucial role in diagnosing and managing these disorders by evaluating clotting function, detecting abnormalities, and monitoring treatment effectiveness for conditions such as hemophilia and thrombosis. For example, the Leukaemia Foundation reported in May 2024 that the number of Australians living with blood cancers or disorders is projected to surpass 275,000 by 2035, highlighting the escalating demand for coagulation markers.

Leading companies in the coagulation markers market are focusing on creating technologically advanced solutions, such as D-dimer kits, to enhance the speed and accuracy of diagnosing blood clot-related conditions. D-dimer kits are diagnostic tools used to measure the levels of D-dimer, a protein fragment produced during the dissolution of a blood clot, which helps in identifying and evaluating clot-related disorders like deep vein thrombosis and pulmonary embolism. For example, in July 2024, Bionote Inc., a US-based biotechnology firm, launched the Vcheck D-dimer 5Tests/Kit. This immunodiagnostic tool, designed for veterinary use, provides five tests per kit to measure D-dimer levels, a key marker for blood clot formation and breakdown. It helps diagnose conditions such as thrombosis, sepsis, and DIC in veterinary clinics.

In January 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired The Binding Site Group for approximately $2.8 billion (£2.3 billion). This acquisition aims to strengthen Thermo Fisher's Specialty Diagnostics portfolio by enhancing cancer diagnostics, particularly in multiple myeloma, and driving growth in the expanding diagnostics market. The Binding Site Group, a UK-based medical equipment manufacturer, specializes in providing coagulation markers.

Major companies operating in the coagulation markers market are Siemens Healthineers, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen Group, Nihon Kohden Corporation, Randox Laboratories Ltd, Stago Group, Sekisui Diagnostics, Helena Laboratories Italia Spa, Tulip Diagnostics Ltd, Trinity Biotech PLC, CTK Biotech Inc., International Technidyne Corporation (ITC), Diazyme Laboratories Inc., AdvaCare Pharma USA (AccuQuik Test Kits), Technoclone GmbH, BioMedica Diagnostics Inc., Eurolyser Diagnostica GmbH, Goldsite Diagnostics Inc., Hipro Biotechnology Co. Ltd., HYPHEN BioMed.

North America was the largest region in the coagulation markers market in 2024. The regions covered in the coagulation markers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coagulation markers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coagulation markers are substances in the blood that provide insight into the coagulation or clotting processes. These markers play a crucial role in diagnosing and monitoring various coagulation disorders, assessing the risk of bleeding or thrombosis, and guiding appropriate treatment strategies.

The main products used as coagulation markers include the D-dimer assay and the fibrinogen assay. The D-dimer assay is a blood test that measures the presence of D-dimer, a protein fragment formed when a blood clot breaks down. This test can utilize different sample types such as plasma or whole blood, employing technologies such as fluorescence immunoassay, enzyme-linked immunosorbent assay (ELISA), rapid tests, and particle-enhanced immunoturbidimetric assay. It is applied in conditions such as deep venous thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), trauma, and others. End users of these assays include hospitals, specialty clinics, academic and research institutes, and diagnostic laboratories.

The coagulation markers market research report is one of a series of new reports that provides coagulation markers market statistics, including coagulation markers industry global market size, regional shares, competitors with a coagulation markers market share, detailed coagulation markers market segments, market trends and opportunities, and any further data you may need to thrive in the coagulation markers industry. This coagulation markers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The coagulation markers market consists of revenues earned by entities providing services such as manufacturing and distribution of coagulation marker testing kits, diagnostic services, research and development of new coagulation markers, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The coagulation markers market also includes sales of coagulation testing kits, point-of-care testing devices, and software solutions for data management and analysis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.